Department of Ophthalmology, Faculty of Medicine, 54562Alexandria University, Alexandria, Egypt.
Department of Ophthalmology, 68900Helwan University, Helwan, Egypt.
Eur J Ophthalmol. 2021 May;31(3):951-958. doi: 10.1177/1120672120928921. Epub 2020 Jun 4.
To study the effect of corneal collagen cross-linking (CXL) using riboflavin and ultraviolet rays on cases of corneal ectasia in keratoconus cases, post-laser-assisted in situ keratomileusis ectasia, and pellucid marginal degeneration and to present its long-term results over many years.
This study was conducted throughout 10 "years" experience in corneal collagen CXL, including 6120 cases. The study consists of two parts: a retrospective and a prospective part. All patients in the retrospective part were operated by epi-off, while in the prospective part, the epi-on procedure was used. Also, other machines were used as Peschke Vario, Peschke Phoenix, and different types of riboflavin. The results were analyzed using SPSS.
The study showed stabilization ectasia in 95% of cases using our standard protocol, and this was proved by topography, pachymetry, refraction, and visual acuity. The effect of CXL was continued in 20% of cases, over a period of 3-5 years, some cases needed to repeat CXL due to the progression of corneal ectasia after cross-linking, in six eyes, that were rubbing their eyes and/or hormonal disturbance.
Corneal collagen cross-linking CXL is an effective method to prevent the progression of corneal ectasia, whether primary or post-laser-assisted in situ keratomileusis, and the effect was stable over the years of study.
研究使用核黄素和紫外线进行角膜胶原交联 (CXL) 对圆锥角膜病例、激光辅助原位角膜磨镶术 (LASIK) 后扩张、透明边缘变性等角膜扩张病例的效果,并展示其多年的长期效果。
本研究在角膜胶原 CXL 的 10 年经验中进行,包括 6120 例病例。该研究由回顾性和前瞻性两部分组成。回顾性部分的所有患者均行上皮下手术,前瞻性部分则采用上皮上手术。此外,还使用了 Peschke Vario、Peschke Phoenix 和不同类型的核黄素等其他机器。结果采用 SPSS 进行分析。
研究表明,使用我们的标准方案,95%的病例稳定了扩张,这通过地形图、角膜厚度、屈光度和视力得到证实。在 20%的病例中,CXL 的效果持续了 3-5 年,由于交联后角膜扩张的进展,有 6 只眼睛需要重复 CXL,这些眼睛是因为揉眼睛和/或激素紊乱。
角膜胶原交联 CXL 是预防角膜扩张进展的有效方法,无论是原发性还是 LASIK 后,在研究的多年中效果稳定。